Abstract
This study analyzes scientific literature regarding the cardiovascular repercussions in survivors of childhood cancer. Using an integrative review approach covering the period from 2013 to 2023, data from databases such as MEDLINE/Pubmed, BVS, and EMBASE were synthesized. Analysis via Iramuteq software identified key thematic clusters. Results indicate that survivors face significant risks of cardiac events, notably coronary artery disease and heart failure, driven by the cardiotoxicity of chemotherapy (anthracyclines) and radiotherapy. Factors such as cumulative dose, age at treatment, and sex further modulate these risks. The study concludes that lifelong cardiovascular monitoring and the implementation of survivorship care plans are essential for this population.
Introduction: The Price of Survival
While advancements in pediatric oncology have pushed survival rates for childhood cancer to nearly 80%, this success comes with a long-term "cardiac footprint." Modern treatments, while effective at eradicating malignancies, often leave survivors with a significantly higher risk of cardiovascular disease compared to the general population. This paper addresses the clinical challenge of late-onset cardiotoxicity, where survivors may appear healthy for decades before developing life-threatening conditions like congestive heart failure or coronary artery disease (CAD).
Methodology
The researchers conducted an integrative review to synthesize findings from diverse study types published between 2013 and 2023.
- Search Strategy: Queries were performed in MEDLINE/PubMed, EMBASE, and the Virtual Health Library (VHL) for articles in English, Portuguese, and Spanish.
- Data Analysis: To minimize researcher bias, the authors utilized Iramuteq software. This tool employs Descending Hierarchical Classification (DHC) to perform lexical analysis on the text corpus, automatically grouping findings into statistically significant thematic classes based on word frequency and correlation.
The final analysis was based on a refined corpus of 8 high-impact peer-reviewed articles, including large-scale cohort studies like the St. Jude Lifetime Cohort, representing data from thousands of patients followed over several decades.
Key Insights: Understanding the Risk
The review highlights several critical factors that define the cardiovascular risk profile for survivors:
The "30-Year Window" and Dose Thresholds
A sobering finding is that approximately 1 in 8 patients treated with anthracyclines or chest radiation will experience a life-threatening cardiovascular event within 30 years of treatment. This risk is heavily dose-dependent. Cumulative doses of anthracyclines (such as doxorubicin) exceeding 250–300 mg/m² are primary predictors of late-onset cardiomyopathy.
Synergistic Treatment Effects
The damage from radiation and chemotherapy is often multiplicative rather than additive. Chest radiation (doses >1500 cGy) causes endothelial damage and fibrosis, which significantly exacerbates the direct myocardial toxicity caused by chemotherapy agents.
Vulnerability Clusters
Risk is not uniform across the survivor population. "Vulnerability clusters" include:
- Female survivors
- Patients treated at a very young age
- Individuals with a family history of heart disease
- Recipients of bone marrow transplants
Results: Clinical Manifestations
The synthesis of the literature reveals stark statistics regarding survivor health:
- Heart Failure Risk: Survivors are 5 to 15 times more likely to develop congestive heart failure than their peers who never had cancer.
- Coronary Artery Disease (CAD): In exposed cohorts, CAD prevalence was approximately 3.8%, often manifesting much earlier than expected in the general population.
- Subclinical Disease: Up to 30.5% of survivors show "moderate risk" for ischemic heart disease or subclinical changes in ejection fraction while still asymptomatic.
- Hypertension (HAS): Survivors with pre-existing or treatment-induced Systemic Arterial Hypertension face a dramatic escalation in the risk of major cardiac events.
Conclusion and Future Directions
Cardiovascular repercussions are lifelong companions for childhood cancer survivors. There is an urgent need for standardized "survivorship care plans" that integrate oncologists, cardiologists, and primary care providers.
Future efforts should focus on:
- Early Detection: Research into biomarkers like Troponin T or NTproBNP to predict heart failure before irreversible structural damage occurs.
- Patient Education: Encouraging self-care and long-term follow-up adherence.
- Refined Protocols: Developing personalized monitoring based on individual risk factors rather than a "one-size-fits-all" approach.
Summary updated